AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8174061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX) with brachytherapy; HFX doses of 1.2 Gy administered twice daily, total dose to the whole pelvis 24-48 Gy, followed by one or two intracavitary applications to deliver a total minimum dose of 85 Gy at point A and 65 Gy to lateral pelvic nodes.
Number of subjects: 81
Study 2883990 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levobunolol 0.5%
Number of subjects: 46
Study 2883990 — intervention group
Group type: COMPARATOR
Intervention: Topical metipranolol 0.6%
Number of subjects: 46
Study 2033413 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam, 0.5 mg three times a day
Number of subjects: 147
Study 2033413 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (behavioral technique)
Number of subjects: 147
Study 1107679 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioisotope-powered pacemaker
Number of subjects: 60
Study 1107679 — intervention group
Group type: COMPARATOR
Intervention: Chemical battery-powered pacemaker
Number of subjects: 60
Study 31264506 — intervention group
Group type: EXPERIMENTAL
Intervention: New chemotherapy
Number of subjects: 0
Study 31264506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayes factor
Number of subjects: 0
Study 31264506 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Bayes false discovery rate
Number of subjects: 0
Study 30677695 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-based intervention
Number of subjects: 23
Study 30677695 — intervention group
Group type: COMPARATOR
Intervention: Human-based intervention
Number of subjects: 23
Study 27860366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sodium citrate (1 mL)
Number of subjects: 49
Study 27860366 — intervention group
Group type: COMPARATOR
Intervention: Physiological sodium chloride solution (1 mL, internal control)
Number of subjects: 49
Study 25105320 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved depression care
Number of subjects: 115
Study 23811030 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary support programme (MSP)
Number of subjects: 447
Study 23811030 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP
Number of subjects: 447
Study 23811030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 447
Study 21486801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 3 months
Number of subjects: 9
Study 21486801 — intervention group
Group type: COMPARATOR
Intervention: Arginase inhibition
Number of subjects: 9
Study 21486801 — intervention group
Group type: COMPARATOR
Intervention: L-arginine supplementation
Number of subjects: 9
Study 21486801 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (arginase inhibition plus L-arginine)
Number of subjects: 9
Study 21486801 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no treatment)
Number of subjects: 9
Study 21486801 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginase activity measurement
Number of subjects: 9
Study 19681799 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwestern Prevention Project (MPP) intervention condition
Number of subjects: 1002
Study 19681799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1002
Study 16916336 — intervention group
Group type: EXPERIMENTAL
Intervention: Written action plans
Number of subjects: 139
Study 16916336 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 139
Study 15518756 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 13
Study 15518756 — intervention group
Group type: COMPARATOR
Intervention: Control group (not meeting selection criteria)
Number of subjects: 13
Study 11387588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (twice weekly group exercise)
Number of subjects: 157
Study 11387588 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched food regimen (daily consumption of foods enriched with vitamins and minerals)
Number of subjects: 157
Study 11387588 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexercising groups followed a social program; nonsupplement groups received the same food products without the micronutrients)
Number of subjects: 157
Study 9425385 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (15 mg/kg)
Number of subjects: 80
Study 9425385 — intervention group
Group type: COMPARATOR
Intervention: Tepid sponging
Number of subjects: 80
Study 8500241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine and isosorbide dinitrate (Hyd-Iso)
Number of subjects: 1446
Study 8500241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1446
Study 8500241 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1446
Study 8500241 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 1446
Study 3115372 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV counselling and antibody testing during the campaign periods
Number of subjects: 700
Study 3115372 — intervention group
Group type: COMPARATOR
Intervention: HIV counselling and antibody testing
Number of subjects: 700
Study 30570787 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with high-dose hypoallergenic birch pollen allergoid
Number of subjects: 253
Study 30570787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 28068954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively and physically demanding exergame intervention (8-week duration, three sessions per week, 30 minutes each)
Number of subjects: 66
Study 28068954 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 66
Study 26256133 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min massage (n = 61)
Number of subjects: 127
Study 26256133 — intervention group
Group type: COMPARATOR
Intervention: Social visit and relaxation session (no massage; n = 66)
Number of subjects: 127
Study 23419987 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐pro‐BNP measured at rest, beginning of the test, maximal effort, and recovery phases
Number of subjects: 57
Study 23419987 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐pro‐BNP measured at rest
Number of subjects: 57
Study 23419987 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔNT‐pro‐BNP from rest to the beginning phase
Number of subjects: 57
Study 23419987 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐pro‐BNP at rest
Number of subjects: 57
Study 23419987 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal NT‐pro‐BNP
Number of subjects: 57
Study 21123220 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 10612
Study 21123220 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy implanted later than 11 months after MI
Number of subjects: 10612
Study 19242135 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental factors (including parental alcohol use, socioeconomic status, and monitoring practices)
Number of subjects: 0
Study 17184491 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg twice daily for 8 weeks
Number of subjects: 19
Study 17184491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 11864854 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary glycemic load
Number of subjects: 244
Study 11864854 — intervention group
Group type: COMPARATOR
Intervention: Low dietary glycemic load
Number of subjects: 244
Study 11864854 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary glycemic load among women with BMI ≥ 25
Number of subjects: 244
Study 11864854 — intervention group
Group type: COMPARATOR
Intervention: Low dietary glycemic load among women with BMI ≥ 25
Number of subjects: 244
Study 11864854 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary glycemic load among women with BMI < 25
Number of subjects: 244
Study 11864854 — intervention group
Group type: COMPARATOR
Intervention: Low dietary glycemic load among women with BMI < 25
Number of subjects: 244
Study 10216048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lensectomy
Number of subjects: 65
Study 10216048 — intervention group
Group type: COMPARATOR
Intervention: Aspiration with primary capsulotomy
Number of subjects: 65
Study 10216048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 65
Study 7814635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopeptide-based therapeutic vaccine (500 micrograms)
Number of subjects: 26
Study 7814635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopeptide-based therapeutic vaccine (5 and 50 micrograms)
Number of subjects: 26
Study 2108855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg rt-PA plus heparin over 4 h
Number of subjects: 83
Study 2108855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg rt-PA over 8 h, repeated in 24 h
Number of subjects: 83
Study 2108855 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus heparin
Number of subjects: 83
Study 2108855 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h infusion of rt-PA
Number of subjects: 83
Study 2108855 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h infusion of rt-PA
Number of subjects: 83
Study 2108855 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than 50% lysis
Number of subjects: 83
Study 2108855 — intervention group
Group type: COMPARATOR
Intervention: Less than 50% lysis
Number of subjects: 83
Study 465276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid release oxprenolol (160 mg)
Number of subjects: 0
Study 465276 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (160 mg)
Number of subjects: 0
Study 29980388 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental intention to vaccinate
Number of subjects: 765
Study 29980388 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective norms related to daughter's doctor
Number of subjects: 765
Study 29980388 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that the vaccine is safe
Number of subjects: 765
Study 29980388 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy to obtain the vaccine for their daughter
Number of subjects: 765
Study 29980388 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental concern about vaccine side effects
Number of subjects: 765
Study 29980388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentions to vaccinate
Number of subjects: 765
Study 29980388 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about sexual disinhibition
Number of subjects: 765
Study 28965384 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloroglucinol combined with parecoxib (80 mg phloroglucinol qd plus 40 mg parecoxib bid for 3 days)
Number of subjects: 98
Study 28965384 — intervention group
Group type: COMPARATOR
Intervention: Phloroglucinol only (80 mg phloroglucinol qd for 3 days)
Number of subjects: 98
Study 24356622 — intervention group
Group type: EXPERIMENTAL
Intervention: panitumumab-FOLFIRI
Number of subjects: 1186
Study 24356622 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 1186
Study 22286639 — intervention group
Group type: EXPERIMENTAL
Intervention: levocetirizine 5 mg
Number of subjects: 27
Study 22286639 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 19711183 — intervention group
Group type: EXPERIMENTAL
Intervention: qEEG-based neurofeedback
Number of subjects: 19
Study 19711183 — intervention group
Group type: EXPERIMENTAL
Intervention: Remedial teaching
Number of subjects: 19
Study 19711183 — intervention group
Group type: COMPARATOR
Intervention: Control group (gender and age matched)
Number of subjects: 19
Study 18293890 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intracoronary injection of CD133+ cells
Number of subjects: 24
Study 18293890 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intracoronary injection of CD133+ cells
Number of subjects: 24
Study 18293890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 15619071 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 15619071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11853774 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-yellow color system
Number of subjects: 0
Study 11853774 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-green color system
Number of subjects: 0
Study 11853774 — intervention group
Group type: EXPERIMENTAL
Intervention: Achromatic system
Number of subjects: 0
Study 11853774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatic system
Number of subjects: 0
Study 10439740 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (44 +/- 11 mg)
Number of subjects: 70
Study 10439740 — intervention group
Group type: COMPARATOR
Intervention: Propofol-ketamine (13.2 +/- 3.3 mg ketamine + 44 +/- 11 mg propofol)
Number of subjects: 70
Study 8552459 — intervention group
Group type: EXPERIMENTAL
Intervention: Images stayed still
Number of subjects: 0
Study 8552459 — intervention group
Group type: EXPERIMENTAL
Intervention: Images moved in an unpredictable direction
Number of subjects: 0
Study 8552459 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey-out period introduced to mimic saccade
Number of subjects: 0
Study 2333838 — intervention group
Group type: COMPARATOR
Intervention: Ordinary food coloring
Number of subjects: 0
Study 2333838 — intervention group
Group type: COMPARATOR
Intervention: Unusual food coloring
Number of subjects: 0
Study 2333838 — intervention group
Group type: COMPARATOR
Intervention: 360 mg monosodium glutamate
Number of subjects: 0
Study 375838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (L.D.H.) prophylaxis
Number of subjects: 86
Study 375838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no low-dose heparin)
Number of subjects: 86
Study 31761458 — intervention group
Group type: EXPERIMENTAL
Intervention: CliniPup® (Group A)
Number of subjects: 72
Study 31761458 — intervention group
Group type: COMPARATOR
Intervention: Empty game without educational information (Group B)
Number of subjects: 72
Study 31761458 — intervention group
Group type: COMPARATOR
Intervention: No game, oral information at the outpatient clinic, current standard of care (Group C)
Number of subjects: 72
Study 30945677 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosses using four genotypes of cauliflower; F1, F2, BC1 and BC2 populations evaluated in a randomized block design.
Number of subjects: 0
Study 29055221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior plate fixation
Number of subjects: 78
Study 29055221 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone cage
Number of subjects: 78
Study 24714934 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 429
Study 24714934 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 429
Study 24714934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 24714934 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg and 40 mg
Number of subjects: 429
Study 23494465 — intervention group
Group type: EXPERIMENTAL
Intervention: Split circumferential semirigid cast
Number of subjects: 100
Study 23494465 — intervention group
Group type: COMPARATOR
Intervention: Closed circumferential semirigid cast
Number of subjects: 100
Study 21435024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light treatment, three times weekly for four weeks
Number of subjects: 20
Study 21435024 — intervention group
Group type: COMPARATOR
Intervention: Red light treatment, three times weekly for four weeks
Number of subjects: 20
Study 19686365 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A 15 U
Number of subjects: 0
Study 19686365 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A 30 U
Number of subjects: 0
Study 19686365 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A 45 U
Number of subjects: 0
Study 19686365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18027255 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening
Number of subjects: 0
Study 18027255 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for men aged 50-70 years
Number of subjects: 0
Study 18027255 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for men with familial risks
Number of subjects: 0
Study 18027255 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern histopathological assessment
Number of subjects: 0
Study 18027255 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of clinically significant cancers
Number of subjects: 0
Study 15020177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Number of subjects: 866
Study 15020177 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 866
Study 12355029 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 2573
Study 9802740 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 99
Study 9802740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 2049255 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride 32 mmol 12 hourly
Number of subjects: 0
Study 2049255 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg 12 hourly
Number of subjects: 0
Study 2049255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2049255 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride vs Spironolactone
Number of subjects: 0
Study 6614411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of retrobulbar local analgesia and light general anaesthesia
Number of subjects: 0
Study 6614411 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 0
Study 30678709 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based application (app) for lifestyle support in addition to traditional cardiac rehabilitation (CR) programs.
Number of subjects: 150
Study 28984033 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (D-group) received a 12-week diet intervention by a dietitian followed by monthly e-mails up to the 1-year follow-up.
Number of subjects: 110
Study 28984033 — intervention group
Group type: COMPARATOR
Intervention: Control group (C-group) received a brochure on healthy eating with no further contact.
Number of subjects: 110
Study 28984033 — intervention group
Group type: EXPERIMENTAL
Intervention: D-group (after excluding women with new pregnancy)
Number of subjects: 110
Study 28984033 — intervention group
Group type: COMPARATOR
Intervention: C-group (after excluding women with new pregnancy)
Number of subjects: 110
Study 28984033 — intervention group
Group type: EXPERIMENTAL
Intervention: D-group
Number of subjects: 110
Study 28984033 — intervention group
Group type: COMPARATOR
Intervention: C-group
Number of subjects: 110
Study 28984033 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who gained weight from 1 to 2 years
Number of subjects: 110
Study 26900698 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament deficient group
Number of subjects: 46
Study 26900698 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 46
Study 24598154 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine supplementation (0.5 mmol ⋅ kg(‐1) ⋅ d(‐1))
Number of subjects: 12
Study 24598154 — intervention group
Group type: COMPARATOR
Intervention: Alanine (control)
Number of subjects: 12
Study 22079052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral myofascial therapy (IMT) consisting of 2 treatment interventions per week for 5 weeks
Number of subjects: 93
Study 22079052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral myofascial therapy plus education and self-care exercises (IMTESC)
Number of subjects: 93
Study 22079052 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 93
Study 20941916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryostimulation and kinesytherapy
Number of subjects: 60
Study 20941916 — intervention group
Group type: COMPARATOR
Intervention: Control group (MS patients without fatigue syndrome)
Number of subjects: 60
Study 18701270 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg for 20-29 kg, 750 mg for 30-39 kg, 1000 mg for 40-49 kg, 1250 mg for >50 kg once a week for 8 weeks
Number of subjects: 38
Study 18701270 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) once a week for 8 weeks
Number of subjects: 38
Study 17023774 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 32
Study 17023774 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (CRT)
Number of subjects: 32
Study 17023774 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal excision (TAE)
Number of subjects: 32
Study 17023774 — intervention group
Group type: COMPARATOR
Intervention: Control group (Radical proctectomy)
Number of subjects: 32
Study 12642834 — intervention group
Group type: COMPARATOR
Intervention: extensively hydrolyzed casein formula (eHF-C)
Number of subjects: 2252
Study 12642834 — intervention group
Group type: COMPARATOR
Intervention: partially hydrolyzed whey formula
Number of subjects: 2252
Study 10657327 — intervention group
Group type: EXPERIMENTAL
Intervention: External hip protectors
Number of subjects: 194
Study 10657327 — intervention group
Group type: COMPARATOR
Intervention: Control group (refusers)
Number of subjects: 194
Study 10657327 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability study
Number of subjects: 194
Study 9117023 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nasal cannula
Number of subjects: 15
Study 9117023 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir nasal cannula
Number of subjects: 15
Study 9117023 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand flow device
Number of subjects: 15
Study 9117023 — intervention group
Group type: COMPARATOR
Intervention: All three systems
Number of subjects: 15
Study 8139136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 7
Study 8139136 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study 3524181 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0